# A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis

> **NCT06989645** · PHASE1,PHASE2 · COMPLETED · sponsor: **Synartro AB** · enrollment: 35 (actual)

## Conditions studied

- Osteoarthritis of Knee

## Interventions

- **DRUG:** SYN321
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06989645
- **Lead sponsor:** Synartro AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-19
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06989645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06989645, "A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06989645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*